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Concise synthesis of (-)-steviamine and analogues and their glycosidase 
inhibitory activities 
Nadechanok Jiangseubchatveera, a,b Marc  E. Bouillon,a Boonsom Liawruangrath,b 
Saisunee Liawruangrath,c Robert J. Nash,d and Stephen G. Pyne*a 
 
A concise synthesis of steviamine is reported along with the synthesis of its analogues 10-nor-steviamine, 
10-nor-ent-steviamine and 5-epi-ent-steviamine. These compounds were tested against twelve 
glycosidases (at 143 g/mL concentrations) and were found to have in general poor inhibitory activity 
against most enzymes. The 10-nor analogues however, showed 50-54% inhibition of -L-rhamnosidase 
from Penicillium decumbens while one of these, 10-nor-steviamine, showed 51% inhibition of N-acetyl-
-D-glucosaminidase (from Jack bean) at the same concentration (760 M). 
Introduction 
(-)-Steviamine 1 is the most recent member of the 
polyhydroxylated indolizidine natural products (Fig. 1). 
Steviamine was isolated from the leaves of Stevia rebaudiana 
(Asteraceae) and its absolute configuration was established by X-
ray crystallographic analysis of its hydrobromide salt.1,2 (-)-
Steviamine 1 is the first polyhydroxylated indolizidine to have a 
methyl group at C-5 and a hydroxymethyl group at C-3. This 
group of alkaloids which includes, swainsonine 2, 
castanosperimine 3 and lentiginosine 4 (Fig. 1) have potential 
utility as antidiabetic, antiviral, anticancer and immunoregulatory 
agents.3 Unlike swainsonine 2, steviamine 1 and its synthesised 
enantiomer  ((+)-steviamine)), have shown  relatively weak to 
modest glycosidase inhibitory activity against a number of 
different glycosidases.4 The most potent activity found in this 
study was against -galactosidase (from rat intestinal lactase), 
where ent-steviamine had an IC50 value of 35 M.
4 While, ent-
steviamine4 and some of its analogues, including 10-nor-
steviamine 5 (and some of its 1,2,3,8a-epimers,),5 5-epi-ent-
steviamine 74 and 1,3-diepi-10-(4- methoxyphenyl)steviamine6 
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Fig. 1 Representative polyhydroxylated indolizidine natural 
products (1-4) and synthetic analogues (5-7).  
 
have been synthesized recently, (-)-steviamine 1 itself has not 
been previously prepared. We report here a concise synthesis of 
steviamine 1 and the synthesis of three analogues, 10-nor-
steviamine 5, 10-nor-ent-steviamine 6 and 5-epi-ent-steviamine 7 
(Fig. 1) and their activities against a panel of twelve glycosidases.  
 
Results and discussion 
The synthesis of (-)-steviamine 1 started with a Petasis boronic 
acid Mannich reaction (PBAMR)7,8 between the known L-β-
ribofuranose derivative 89 ((3S,4R,5S)-4-(benzyloxy)-5-
(benzyloxymethyl)tetrahydrofuran-2,3-diol) and commercially 
available (R)-4-penten-2-amine.HCl 9a and E-styrylboronic acid 
10 (Scheme 1). Stirring these three components in the presence of 
triethylamine (to generate the free amine of 9a) in ethanol at rt for 
4 d, gave, after purification of the crude reaction mixture by 
column chromatography, the amino alcohol 11 in 77% yield, as a 
single diastereomer. Shorter reaction times (1-2 d) and other 
solvents (e.g. MeOH, CH2Cl2 and MeCN) gave lower yields. The 
configuration at the newly created, amino group bearing, 
stereogenic centre in 11a, that would become C-8a in the final 
target 1, was assumed to the desired one based on reports that the 
 
 
PBAMR normally provides 1,2-anti-amino alcohol products via a 
boronate intermediate, similar to A, as shown in Scheme 1.7,8 
This assumption was later confirmed to be correct in the eventual 
execution of the synthesis of 1. Treatment of 11a with 1.07 
equivalents of methanesulfonyl chloride and 3.5 equivalents of 
triethylamine,8(g) followed by warming of the O-mesylate 
intermediate to 40−45 oC for 4 h provided the fully substituted 
pyrrolidine 12a in 66% yield after separation of small amounts of 
O,N-dimesylated 11a and unreacted 11a by column 
chromatography. A ring-closing metathesis reaction of diene 11a 
using 18 mol% Grubbs’ second generation catalyst, in the 
presence of Ti(OiPr)4 (0.2 equivalents)
8b,10 to deactivate the 
amino group in 11a, gave the indolizidine 12a in 76% yield. 
Hydrogenation/hydrogenolysis of 12a, over PdCl2/H2
8c gave (-)-
steviamine 1 in quantitative yield after neutralization/purification 
by basic ion-exchange chromatography. 
 The NMR spectroscopic data of synthetic 1, matched very 
closely (1H NMR 0.1 ppm consistent differences, 13C NMR .04 
ppm consistent differences) to those of the natural product2 (see 
the Electronic Supplementary Information (ESI)). Further the 
specific rotation of the synthetic material, [α]D
25 -23.8 (c 1.0, 
MeOH), was of the same sign and close in magnitude to that of 
the natural product (lit.2 [α]D
20 -22 (c 1.0, MeOH). Thus the first 
synthesis of (-)-steviamine 1 has been achieved in four synthetic 
steps from compounds 8, 9a and 10. Since compound 8 was 
prepared in four steps (45% overall yield (see ESI)) from 
commercially available β-L-ribofuranose-1,2,3,5-tetra-O-acetate, 
this synthesis represents an eight step total synthesis of 
steviamine 1 from commercially available starting materials with 
an over yield of 17%. This concise strategy was further employed 
to prepare the analogues 5, 6 and 7.   
 Treatment of a mixture of 8, 4-buten-1-amine.HCl 9b and 10 
under the aforementioned PBAMR conditions gave the amino 
diol 11b as a single diastereomer in 59% yield (Scheme 1). This 
compound was converted to 10-nor-steviaimine 5, in an 
analogues fashion, in 30% overall yield (Scheme 1). While this 
compound had a specific rotation of [α]D
25 -7.7 (c 1.0, H2O), 
similar to that reported in the literature ([α]D
25 -8.7 (c 1.2, H2O),
5 
there were significant differences in the 1H NMR spectral data 
recorded in D2O (see ESI). The most significant difference was 
the relative chemical shifts for the protons H-1 and H-9a and H-
9b in the range of  ~ 3.8-3.9. In our sample the H9 protons were 
observed as dd resonances (J = 12.0, 5.0-5.5 Hz) at  3.87 and  
3.81 while the H-1 resonance at 3.82 (apparent t, J = 6.0 Hz) 
was observed at a chemical shift in between those of the two H-9 
resonances. The literature, however, reported the H9 protons as 











































Scheme 1 Synthesis of steviamine 1 and 10-nor-steviamine 5 and 
its triacetate derivative 14. 
 
H-1 signal being the most downfield of this group at 3.87 
(apparent t, J = 5.5 Hz). Further, H-8a resonated at 2.67-2.72 
(m) in our sample while the literature value for the chemical shift 
of this proton was  2.97 (s). The 13C NMR chemical shifts were 
also significantly different with chemical shift differences 
varying from -1.9 to 0.2 ppm (see ESI). Since NOESY and 
ROESY NMR experiments on our sample of 5 were not 
unequivocal in defining the stereochemistry of our compound, 
because of the closeness of the individual resonances, and 
because the NMR chemical shifts of these types of 
polyhydroxylated compounds in D2O can vary with pH and 
concentration,8d,f we prepared 14, the triacetate derivative of 5 
(Scheme 1). ROESY NMR experiments in CDCl3 clearly 
indicated the assigned stereochemistry of 14. Significant cross 
peaks were observed between H-8a and both H-5 and H-9, 
which clearly supported the relative syn-stereochemical 
relationship between these three protons (Fig. 2). 
 For the synthesis of 5-epi-ent-steviamine 7 the known D-β-
ribofuranose derivative 159 ((3R,4S,5R)-4-(benzyloxy)-5-
(benzyloxymethyl)tetrahydrofuran-2,3-diol) was treated with (R)-
4-penten-2-amine.HCl 9a, triethylamine and E-styrylboronic acid 
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Fig. 2 Significant ROESY cross-peaks of compound 14 
(SPARTAN generated structure using a DFT calculation 
(B3LYP/6-31G** level)).  
 
82% yield (Scheme 2). This compound was readily converted to 
5-epi-ent-steviamine 7 in three efficient steps according to the 
protocols developed in Scheme 1. The overall yield of 7 was 38% 
from 15 or 24% from D-β-ribofuranose. The NMR spectroscopic 
data of 7 agreed well with those reported2 (see ESI), the specific 
rotation of 7 ([α]D
25 -4.6 (c 1.0, MeOH)) was of the same sign and 
of similar low magnitude to that reported ([α]D




























Scheme 2 Synthesis of 5-epi-ent-steviamine 7, 10-nor-ent-
steviamine 6 and its triacetate derivative 19. 
 10-Nor-ent-steviamine 6 and its triacetate derivative 19 were 
prepared in an analogous fashion from 15 (Scheme 2). The NMR 
spectroscopic data of 5 and 6 and those of 14 and 19 were 
identical, allowing for slight spectrometer variations. While the 
optical rotations of 5 and 6 were opposite in sign they varied 
significantly in magnitude (see Experimental section), however 
those of compounds 14 and 19, which could be purified on silica 
gel using organic solvents, were essentially equal and opposite in 
sign (14: [α]D
25 +9.4 (c 0.2, CHCl3); 19: [α]D
25 -9.2 (c 0.2, 
CHCl3)). These results suggested that the samples of 5 or 6 may 
be different hydrates resulting in incorrect mass measurements. 
Repeated purifications of these samples did not provide more 
closely matching specific rotations. 
 
Glycosidase inhibition studies 
 
The results of our glycosidase inhibitor testing for (-)-steviamine 
1, its analogues 5-7 and swainsonine 2, ent-2 and 
castanosperimine 3 against twelve glycosidases are shown in 
    
Table 1 The glycosidase inhibition of compounds 1, and 5-7 (Mean 
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17a, R = Me [69%]





18a, R = Me [83%]















7, R = Me, R1 = H [100%]
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Table 1. These mean % inhibition tests were determined for each 
compound at 143 g/mL according to previously published 
protocols.11 In general compounds 1 and 5−7 were found to have 
poor inhibitory activity against most enzymes. None were as 
active as (-)-swainsonine 2 against -L-rhamnosidase (from 
Penicillium decumbens) or (+)-swainsonine(ent-2) against-D-
mannosidase (from Jack bean) or castanospermine 3 against D-
glycosidase (from Bacillus sterothermophilus) and almond -D-
glycosidase. The 10-nor analogues, 5 and 6, however, showed 
50-54% inhibition of -L-rhamnosidase from Penicillium 
decumbens while 10-nor-steviamine 5, showed 51% inhibition of 
N-acetyl--D-glucosaminidase (from bovine kidney) at the same 
concentration (760 M). It is interesting that the enantiomeric 
compounds 5 and 6 give almost equal inhibition of -L-
rhamnosidase  whereas 7, with the extra methyl group, is a much 
weaker inhibitor. Both 5 and 6 have two equivalent hydroxyls to 
(+)-swainsonine (ent-2) and (-)-swainsonine 2, respectively and 
yet they both follow (-)-swainsonine 2 in inhibition of -L-
rhamnosidase and not -mannosidase. (-)-Steviamine 1 does not 
show significant inhibition of any glycosidase tested; it could be 
that it has a biological function in the source plant inhibiting a 
glycosidase we have not tested against or it is clear that 
iminosugars can be functional without glycosidase inhibition and 
in fact this lack of glycosidase inhibition (or high selectivity) may 
make them more suitable as pharmaceutical products.12 
Interestingly, all compounds appeared to promote the activities of 
certain enzymes. In particular, compounds 1 and 6 seemed to 
significantly promote the activity of -D-glucosidase (from 
Bacillus sterothermophilus). This promotion of activity could be 
due to enzyme stabilisation or improved folding of the enzyme 
via non-catalytic site binding.  
 
The inhibitory activity of compound 5, which was prepared 
previously5, and had different NMR properties to ours, was 
reported to have no inhibitory activity against two -D-
glucosidases (from Baker’s yeast and rice), one -D-glucosidase 
(from sweet almonds) and a -D-galactosidase (from bovine 
liver). These results are consistent with our results shown in 
Table 1. The earlier report showed that compound 5 was a more 
significant inhibitor of -L-rhamnosidase (from Penicillium 
decumbens, IC50 35 M)) and -D-mannosidase (from Jack bean, 
IC50 82 M)) and a significantly weaker inhibitor of -L-
fucosidase (from bovine kidney, IC50 593 M)). Our compound 5 
also showed some, although very weak, activity against -D-
mannosidase (from Jack bean, only 31% inhibition at 708, M 
Table 1) and an IC50 of approximately 708 M (53% inhibition) 
against the -L-rhamnosidase from Penicillium decumbens.  
Conclusions 
In conclusion, a concise and efficient four step synthesis of 
natural (-)-steviamine 1 has been developed from the readily 
accessible L-β-ribofuranose derivative 8. This synthetic protocol 
involves a highly anti-selective Petasis reaction, and efficient 
ring-closing metathesis and O-mesylate cyclization reactions to 
prepare the piperidine and pyrrolidine rings, respectively. This 
synthetic protocol allowed for the synthesis of the (-)-steviamine 
analogues 10-nor-steviamine, 10-nor-ent-steviamine and 5-epi-
ent-steviamine. These compounds were tested against twelve 
glycosidases (at 143 g/mL concentrations) and were found in 
general to have poor inhibitory activity against most enzymes. 
The 10-nor analogues however, showed 50-54% inhibition of -
L-rhamnosidase from Penicillium decumbens while one of these, 
10-nor-steviamine, showed 51% inhibition of N-acetyl--D-






All reagents were used as received from commercial sources 
without further purification. Solvents were purchased as 
Analytical Reagents (AR) grade. Petrol refers to the hydrocarbon 
fraction of bp 40-60 °C. Tetrahydrofuran was stored over KOH 
pellets until needed, then distilled over sodium wire under 
nitrogen, using benzophenone as indicator. Anhydrous CH2Cl2 
and MeOH were purchased from Aldrich. Reactions were stirred 
using Teflon-coated magnetic stirring bars. Analytical TLC was 
performed with aluminium backed Merck F254 sorbent silica gel. 
TLC plates were visualized by ultraviolet light or by treatment 
with acidified, aqueous solution of ammonium molybdate and 
cerium(IV) sulfate, followed by development with a 1400 Watt 
heat gun. Chromatographic purification of products was carried 
out by flash column chromatography on silica gel (70-230 mesh). 
Basic ion-exchange chromatography was performed using 
Amberlyst A-26(OH) resin. Infrared spectra were recorded as 
neat samples on a MIRacle 10 Shimadzu Spectrophotometer. 
NMR spectra were measured in CDCl3 (with TMS as internal 
standard) or D2O (with MeOH as internal standard) on a Varian 
VNMRS PS54-500 or a Varian INOVA-500 (1H at 500 MHz, 13C 
at 125 MHz) magnetic resonance spectrometer. Chemical shifts 
(δ) are reported in ppm, and coupling constants (J) are in Hz. The 
following abbreviations were used to explain the multiplicities: s 
= singlet, d = doublet, t = triplet, q = quartet, m = multiplet. Low-
resolution mass spectra were obtained on a Waters LCZ single 
quadropole (ESI). High-resolution mass spectra (HRMS) were 
recorded on a Waters QTOF (ESI), a Waters Xevo (ESI) or a 
Waters Xevo (ASAP). Polarimetry was carried out using a 
JASCO P-2000 Digital Polarimeter and the measurements were 
made at the sodium D-line with a 1 dm path length cell. 
Concentrations (c) are given in grams per 100 mL. 
 
(2S,3R,4R,E)-1,3-Bis(benzyloxy)-5-((R)-pent-4-en-2-ylamino)-
7-phenylhept-6-ene-2,4-diol (11a). To a solution of 8 (1.00 g, 
3.03 mmol, see ESI for synthesis details) in absolute ethanol (25 
mL) was added (R)-pent-4-en-2-amine.hydrochloride 9a (368 mg, 
 
 
3.03 mmol, a commercial sample from NetChem, Inc. USA,  
>95% ee, [α]D
25
 +4.0 (c 1.0, EtOH)) followed by Et3N (0.42 mL, 
3.03 mmol) and trans-2-phenylvinyl boronic acid (10) (448 mg, 
3.03 mmol, commercial sample from Aldrich). The mixture was 
stirred at rt for 4 d, followed by the evaporation of all volatiles in 
vacuo. The residue was dissolved in CH2Cl2 (10 mL) and washed 
with sat. aq. NaHCO3 (2×10 mL). The organic layer was dried 
(MgSO4), filtered and concentrated in vacuo to afford a brown 
foam. Purification by flash column chromatography (increasing 
polarity from 0:100 to 20:80 MeOH/CH2Cl2 as eluent) afforded 
the title compound (1.16 g, 77%) as a yellow foam. Rf 0.48 
(10:90 MeOH/CH2Cl2). [α]D
25
 +47.9 (c 2.0, CHCl3). IR (cm
-1): 
3289, 3072, 1452, 1072, 1028. 1H NMR (500 MHz, CDCl3) δ 
7.41−7.20 (m, 15H), 6.47 (d, J = 16.0 Hz, 1H), 6.16 (dd, J = 16.0, 
9.0 Hz, 1H), 5.75−5.67 (m, 1H), 5.05 (d, J = 16.0 Hz, 1H), 5.04 
(d, J = 12.0 Hz, 1H), 4.63, 4.54 (ABq, JAB = 12.0 Hz, 2H), 4.56, 
4.48 (ABq, JAB = 11.5 Hz, 2H), 4.06−4.03 (m, 1H), 3.95 (t, J = 4.5 
Hz, 1H), 3.78 (dd, J = 9.0, 5.0 Hz, 1H), 3.75-3.66 (ma, 3H), 
2.88−2.76 (m, 1H), 2.22−2.10 (ma, 2H), 1.04 (d, J = 6.5 Hz, 3H) 
[a indicates the overlapping of signals]. 13C NMR (125 MHz, 
CDCl3) δ 138.4, 138.2, 136.5, 135.1, 133.9, 128.7, 128.5, 128.0, 
127.9, 127.7, 126.5, 127.5, 117.9, 80.0, 74.0, 73.7, 73.0, 71.7, 
69.1, 59.6, 49.2, 42.1, 19.2. MS (ESI +ve) m/z 502.4 (M+H+, 
100%). HRMS (ESI +ve) calculated for C32H40NO4 (M+H
+) 
502.2957, found 502.2938. 
 
(2R,3R,4S,5R)-4-(Benzyloxy)-5-(benzyloxymethyl)-1-((R)-
pent-4-en-2-yl)-2-styrylpyrrolidin-3-ol (12a). To a solution of 
11a (1.02 g, 2.02 mmol) in anhydrous CH2Cl2 (6 mL) at 0 °C was 
added Et3N (0.99 mL, 7.08 mmol) under an atmosphere of N2. 
The mixture was then cooled to -10 °C followed by the addition 
of a 0.13 M solution of methanesulfonyl chloride in anhydrous 
CH2Cl2 (17.0 mL, 2.18 mmol MeSO2Cl) . After complete 
addition the reaction mixture was gradually warmed to 40 °C 
over 3 h and stirred for further 30 min with heating under a gentle 
reflux. The solution was subsequently concentrated in vacuo to 
afford a brown oil. Purification by flash column chromatography 
(increasing polarity from 10:90 to 20:80 EtOAc/petrol and 20:80 
MeOH/CH2Cl2 as eluent) afforded the title compound (642.2 mg, 
66%) as a yellow oil. Rf 0.62 (3:7 EtOAc/petrol). [α]D
25
 -29.4 (c 
1.0, CHCl3). IR (cm
-1): 3393, 3062, 3027, 2906, 2869, 1496, 
1452, 1365, 1178, 1138, 1116, 1098, 1055, 1026. 1H NMR (500 
MHz, CDCl3) δ 7.35−7.19 (m, 15H), 6.52 (d, J = 16.0 Hz, 1H), 
5.97 (dd, J = 16.0, 9.0 Hz, 1H), 5.84−5.76 (m, 1H), 5.03 (d, J = 
17.0 Hz, 1H), 4.97 (d, J = 10.0 Hz, 1H), 4.76, 4.48 (ABq, JAB = 
12.0 Hz, 2H), 4.62 (d, J = 10.5 Hz, 1H), 4.59, 4.55 (ABq, JAB = 
12.0 Hz, 2H), 4.15 (t, J = 5.5 Hz, 1H), 3.97 (dd, J = 10.5, 5.5 Hz, 
1H), 3.88 (d, J = 9.0 Hz, 1H), 3.62−3.56 (ma, 3H), 3.08-3.02 (m, 
1H), 2.40−2.34 (m, 1H), 2.17−2.11 (m, 1H), 1.03 (d, J = 6.5 Hz, 
1H) [a indicates the overlapping of signals]. 13C NMR (125 MHz, 
CDCl3) δ 138.5, 137.6, 137.3, 137.2, 132.5, 130.5, 128.7, 128.5, 
128.4, 127.9, 127.7, 127.4, 126.4, 115.7, 77.9, 74.9, 73.8, 71.4, 
70.0, 68.0, 58.9, 51.4, 39.6, 17.9. MS (ESI +ve) m/z 484.3 
(M+H+, 100%). HRMS (ESI +ve) calculated for C32H38NO3 
(M+H+) 484.2852, found 484.2832. 
 
((1R,2S,3R,5R,8aR)-2-(Benzyloxy)-3-(benzyloxymethyl)-5-
methyl-1,2,3,5,6,8a-hexahydroindolizin-1-ol (13a). To a 
solution of 12a (490.7 mg, 1.02 mmol) in anhydrous CH2Cl2 (36 
mL) was added via syringe a solution of Ti(Oi-Pr)4 (0.06 mL, 
0.203 mmol) in anhydrous CH2Cl2 (11 mL). The above solution 
was stirred at rt for 0.5 h, then added Grubbs II catalyst (155.3 
mg, 0.183 mmol). The reaction mixture was heated at reflux at 45 
°C for 2.5 h, when TLC analysis showed complete consumption 
of 12a. The reaction mixture was then diluted with CH2Cl2 (125 
mL) and washed with sat. aq. NaHCO3 (87 mL). The aqueous 
layer was further extracted with CH2Cl2 (125 mL). The organic 
layers were dried (MgSO4) and concentrated in vacuo to afford a 
dark brown oil as a crude product. Purification by flash column 
chromatography (increasing polarity from 50:50 to 0:100 
petrol/EtOAc as eluent) afforded the title compound (294 mg, 
76%) as a brown oil. Rf 0.28 (1:4 petrol/EtOAc). [α]D
25
 +38.6 (c 
1.4, CHCl3). IR (cm
-1): 3382, 3015, 2928, 2874, 2316, 1496, 
1451, 1152, 1055. 1H NMR (500 MHz, CDCl3) δ 7.34−7.21 (m, 
10H), 5.79−5.76 (m, 1H), 5.53 (d, J = 10.5 Hz, 1H), 4.93 (d, J = 
9.5 Hz, 1H), 4.71, 4.45 (ABq, JAB = 11.5 Hz, 2H), 4.69, 4.54 
(ABq, JAB = 12.0 Hz, 2H), 4.12 (dd, J = 9.5, 4.5 Hz, 1H), 3.97 
(dd, J = 9.5, 4.5 Hz, 1H), 3.91 (brs, 1H), 3.58 (d, J = 9.0 Hz, 1H), 
3.41 (dd, J = 9.5, 3.0 Hz, 1H), 3.34 (brd, J = 9.5 Hz, 1H), 
3.27−3.20 (m, 1H), 2.04−1.98 (m, 1H), 1.77−1.72 (m, 1H), 1.17 
(d, J = 7.0 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 138.4, 137.5, 
129.1, 128.4, 128.3, 128.2, 127.8, 127.6, 127.7, 78.2, 74.0, 71.5, 
71.5, 70.6, 66.7, 55.7, 50.6, 26.1, 21.3. MS (ESI +ve) m/z 380.2 
(M+H+, 100%). HRMS (ESI +ve) calculated for C24H30NO3 
(M+H+) 380.2226, found 380.2214. 
  
(1R,2S,3R,5R,8aR)-3-(Hydroxymethyl)-5-
methyloctahydroindolizine-1,2-diol ((-)-Steviamine) (1). To a 
solution of 13a (183.5 mg, 0.484 mmol) in MeOH (10 mL) was 
added PdCl2 (171.5 mg, 0.967 mmol). The mixture was stirred at 
rt under an atmosphere of H2 (balloon) for 3 h. The mixture was 
filtered through a pad of Celite and the solids were washed with 
MeOH. The combined filtrates were evaporated in vacuo and the 
residue was dissolved in water (10 mL) and applied to a column 
of Amberlyst A-26 (OH-) resin (3 cm). Elution with water 
followed by evaporation in vacuo afforded the title compound 
(98.0 mg, 100%) as a brown oil. [α]D
25
 - 23.8 (c 1.0, MeOH) (lit.2 
[α]D
25
 -22.0 (c 1.0, MeOH)). IR (cm-1): 3329, 2929, 2855, 1631, 
1441, 1379, 1315, 1214, 1137, 1097, 1079, 1036, 1006. 
1H NMR (500 MHz, D2O) δ 4.33 (t, J = 7.5 Hz, 1H, H-2), 3.96 
(dd, J = 12.5, 5.5 Hz, 1H, H-9), 3.91 (dd, J = 12.0, 3.5 Hz, 1H, H-
9'), 3.80 (t, J = 7.0 Hz, 1H, H-1), 3.52 (dd, J = 9.5, 6.5 Hz, 1H, H-
3), 2.85−2.82 (m, 1H, H-5), 2.67−2.64 (m, 1H, H-8a), 2.00 (brd, J 
= 12.5 Hz, 1H, H-8), 1.81 (brd, J = 13.0 Hz, 1H, H-7), 1.74 (brd, 
J = 13.0 Hz, 1H, H-6), 1.42−1.34 (m, 1H, H-7'), 1.21−1.12 (ma, 
5H, H-6', H-8' and CH3) [
a = overlapping of signals].13C NMR 
(125 MHz, D2O) δ 74.1 (C-1), 69.3 (C-2), 66.9 (C-8a), 61.5 (C-
3), 56.7 (C-9), 52.8 (C-5), 33.6 (C-6), 29.5 (C-8), 23.9 (C-7), 19.4 
(CH3). MS (ESI +ve) m/z 202.0 (M+H
+, 100%). HRMS (ESI +ve) 
calculated for C10H20NO3 (M+H
+) 202.1443, found 202.1465. 
 
((2S,3R,4R,E)-1,3-Bis(benzyloxy)-5-(but-3-enylamino)-7-
phenylhept-6-ene-2,4-diol (11b) and its enantiomer 16b. To a 
solution of 8 (30.4 mg, 0.09 mmol) in absolute EtOH (0.75 mL) 
was added 3-butenylamine.hydrochloride (9b) (9.7 mg, 0.09 
mmol) followed by Et3N (0.013 mL, 0.09 mmol) and trans-2-
phenylvinyl boronic acid (10) (13.3 mg, 0.09 mmol). The mixture 
was stirred at rt for 4 d, followed by the evaporation of all 
volatiles in vacuo. The residue was dissolved in CH2Cl2 (4 mL) 
and washed with sat. aq. NaHCO3 (2×4 mL). The organic layer 
was dried (MgSO4), filtered and concentrated in vacuo to afford a 
brown foam. Purification by flash column chromatography 
(increasing polarity from 0:100 to 20:80 MeOH/CH2Cl2 as 
eluent) afforded the title compound (26.3 mg, 59%) as a brown 
foam. Rf 0.45 (10:90 MeOH/CH2Cl2). [α]D
25
 +51.5 (c 1.3, CHCl3). 
IR (cm-1): 3376, 3029, 1452, 1088, 1072, 1028. 1H NMR (500 
MHz, CDCl3) δ 7.39−7.19 (m, 15H), 6.51 (d, J = 16.0 Hz, 1H), 
6.23 (dd, J = 16.0, 9.0, 1H), 5.77−5.67 ( m, 1H), 5.07 (d, J = 18.0 
 
 
Hz, 1H), 5.03 (d, J = 10.5 Hz, 1H), 4.64, 4.56 (ABq, JAB = 12.5 
Hz, 2H), 4.55, 4.47 (ABq, JAB = 11.5 Hz, 2H), 4.04−4.00 (m
a, 
2H), 3.75−3.68 (ma, 3H), 3.65 (dd, J = 7.0, 4.5 Hz, 1H), 
2.76−2.71 (m, 1H), 2.60−2.55 (m, 1H), 2.26 (q, J = 7.0 Hz, 2H) 
[a = overlapping of signals]. 13C NMR (125 MHz, CDCl3) δ 
138.5, 138.0, 136.4, 135.7, 134.6, 128.8, 128.5, 128.1, 128.0, 
127.9, 127.7, 126.8, 126.8, 117.1, 79.7, 73.8, 73.5, 72.9, 71.7, 
68.8, 62.8, 46.0, 33.8. MS (ESI +ve) m/z 488.5 (M+H+, 100%). 
HRMS (ESI +ve) calculated for C31H38NO4 (M+H
+) 488.2801, 
found 488.2784. 
Its enantiomer (16b) was prepared as described above using 15 
(see ESI for syntheses details) as a starting material (0.605 mmol 
scale). Compound 16b was obtained as a brown foam (167.9 mg, 
57%). [α]D
25
 -58.7 (c 1.0, CHCl3). 
 
(2R,3R,4S,5R)-4-(Benzyloxy)-5-(benzyloxymethyl)-1-(but-3-
enyl)-2-styrylpyrrolidin-3-ol (12b) and its enantiomer 17b. To 
a solution of 11b (80.0 mg, 0.1641 mmol) in anhydrous CH2Cl2 
(9 mL) at 0 °C was added Et3N (0.023 mL, 0.164 mmol) under an 
atmosphere of N2. The mixture was then cooled to -10 °C 
followed by the addition of a 0.13 M solution of methanesulfonyl 
chloride in anhydrous CH2Cl2 (1.51 mL, 0.197 mmol MeSO2Cl). 
After complete addition the reaction mixture was gradually 
warmed to 40 °C over 3 h and stirred for further 30 min under 
gentle reflux. The solution was subsequently concentrated in 
vacuo to afford a brown oil. Purification by flash column 
chromatography (increasing polarity from 10:90 to 20:80 
EtOAc/petrol and 20:80 MeOH/CH2Cl2 as eluent) afforded the 
title compound (63.9 mg, 83%) as a yellow oil. Rf 0.52 (3:7 
EtOAc/petrol). [α]D
25
 -18.2 (c 0.7, CHCl3). MS (ESI +ve) m/z 
470.4 (M+H+, 100%). HRMS (ESI +ve) calculated for 
C31H36NO3 (M+H
+) 470.2695, found 470.2674. IR (cm-1): 3405, 
3061, 3028, 2863, 1640, 1599, 1495, 1452, 1363, 1099, 1055. 1H 
NMR (500 MHz, CDCl3) δ 7.35−7.20 (m, 15H), 6.56 (d, J = 16.0 
Hz, 1H), 6.03 (dd, J = 16.0, 9.0 Hz, 1H), 5.79−5.72 (m, 1H), 4.99 
(d, J = 17.0 Hz, 1H), 4.95 (d, J = 10.0 Hz, 1H), 4.76, 4.51 (ABq, 
JAB = 12.0 Hz, 2H), 4.60, 4.57 (ABq, JAB = 12.0 Hz, 2H), 4.18 (t, J 
= 7.0 Hz, 1H), 4.01 (brs, 1H), 3.69−3.61 (ma, 3H), 3.43 (d, J = 
8.0 Hz, 1H), 2.78−2.66 (m, 2H), 2.25−2.14 (m, 2H) [a indicates 
the overlapping of signals]. 13C NMR (125 MHz, CDCl3) δ 138.4, 
137.6, 137.1, 136.9, 131.8, 130.3, 128.7, 128.6, 128.5 , 128.0, 
127.9, 127.8, 127.6, 126.5, 115.6, 77.6, 74.7, 73.8, 73.4, 71.8, 
66.4, 61.4, 47.9, 33.1. 
Its enantiomer (17b) was prepared from 16b (0.3341 mmol scale) 
as described above. Compound 17b was obtained as a yellow oil 
(90.5 mg, 58%). [α]D
25
 +35.4 (c 0.8, CHCl3). 
 
(1R,2S,3R,8aR)-2-(Benzyloxy)-3-(benzyloxymethyl)-
1,2,3,5,6,8a-hexahydroindolizin-1-ol (13b) and its enantiomer 
18b. To a solution of 12b (63.9 mg, 0.136 mmol) in anhydrous 
CH2Cl2 (4.8 mL) was added via syringe a solution of Ti(O
i-Pr)4  
(0.008 mL, 0.027 mmol) in anhydrous CH2Cl2 (1.6 mL). The 
above solution was stirred at rt for 0.5 h, then Grubbs II catalyst 
was added (13.84 mg, 0.016 mmol). The reaction mixture was 
heated at reflux at 45 °C for 2.5 h, when TLC analysis showed 
complete consumption of 12b. The reaction mixture was then 
diluted with CH2Cl2 (17 mL) and washed with sat. aq. NaHCO3 
(11 mL). The aqueous layer was further extracted with CH2Cl2 
(17 mL). The organic layers were dried (MgSO4) and 
concentrated in vacuo to afford a dark brown oil. Purification by 
flash column chromatography (increasing polarity from 20:80 to 
10:90 petrol/EtOAc and 20:80 MeOH/CH2Cl2 as eluent) afforded 
the title compound (30.9 mg, 62%) as a brown oil. Rf 0.28 (1:4 
petrol: EtOAc). [α]D
25
 +108.9 (c 0.2, CHCl3). MS (ESI +ve) m/z 
366.3 (M+H+, 100%). HRMS (ESI +ve) calculated for 
C23H28NO3 (M+H
+) 366.2069, found 366.2053. IR (cm-1): 3259, 
2922, 2854, 2364, 1731, 1631, 1452, 1362, 1143, 1084, 1025. 1H 
NMR (500 MHz, CDCl3) δ 7.36−7.25 (m, 10H), 5.84−5.82 (m, 
1H), 5.62 (d, J = 9.0 Hz, 1H), 4.68, 4.54 (ABq, JAB = 11.5 Hz, 
2H),4.62, 4.53 (ABq, JAB = 11.5 Hz, 2H), 4.15 (dd, J = 7.5, 4.0 
Hz, 1H), 3.96 (brs, 1H), 3.77 (brs, 1H), 3.63 (dd, J = 9.5, 4.5 Hz, 
1H), 3.55 (dd, J = 9.5, 3.0 Hz, 1H), 3.29−3.27 (m, 1H), 3.04−3.00 
(ma, 2H), 2.24−2.22 (m, 1H), 1.77 (d, J = 17.5 Hz, 1H). [a = 
overlapping of signals] 13C NMR (125 MHz, CDCl3) δ 138.2, 
137.9, 128.5, 128.4, 128.4, 128.1, 127.9, 127.8, 127.7, 127.2, 
78.6, 73.9, 73.4, 72.6, 68.8, 64.2, 60.9, 44.6, 19.3. 
Its enantiomer (18b) was prepared from 17b (0.182 mmol scale) 
as described as above. Compound 18b was obtained as a brown 
oil (41.8 mg, 63%). [α]D
25
 -114.5 (c 0.2, CHCl3). 
 
(1R,2S,3R,8aR)-3-(Hydroxymethyl)octahydroindolizine-1,2-
diol (10-nor-steviamine) (5) and its enantiomer 6. To a solution 
of 13b (28.6 mg, 0.078 mmol) in MeOH (1.7 mL) was added 
PdCl2 (20.8 mg, 0.117 mmol). The mixture was stirred at rt under 
an atmosphere of H2 (balloon) for 3 h. The mixture was filtered 
through a pad of Celite and the solids were washed with MeOH. 
The combined filtrates were evaporated in vacuo and the residue 
was dissolved in water (1.5 mL) and applied to a column of 
Amberlyst A-26 (OH-) resin (3 cm). Elution with water followed 
by evaporation in vacuo afforded the title compound (14.6 mg, 
100%) as a brown oil. [α]D
25
 -7.7 (c 0.6, H2O), [α]D
25
 -11.4 (c 0.6, 
MeOH) (lit.5 [α]D
22
 -8.7 (c 1.2, H2O)). IR (cm
-1): 3324, 2929, 
1636, 1596, 1445, 1141, 1105, 1083, 1049, 1007. 1H NMR (500 
MHz, D2O) δ 4.40 (t, J = 6.5 Hz, 1H, H-2), 3.87 (dd, J = 12.0, 5.5 
Hz, 1H, H-9), 3.82 (t, J = 6.0 Hz, 1H, H-1), 3.81 (dd, J = 12.0, 
5.0 Hz, 1H, H-9'), 3.30 (dd, J = 12.5, 5.5 Hz, 1H, H-3), 2.96−2.93 
(m, 1H, H-5α), 2.76-2.74 (m, 1H, H-8a), 2.72-2.67 (m, 1H, H-
5β), 1.87−1.84 (m, 1H, H-8), 1.80−1.76 (m, 1H, H-7), 1.62−1.58 
(m, 1H, H-6), 1.54−1.46 (m, 1H, H-6'), 1.41−1.32 (m, 1H, H-7'), 
1.29−1.21 (m, 1H, H-8'). 13C NMR (125 MHz, D2O) δ 74.5 (C-
1), 70.1 (C-2), 64.0 (C-3), 63.8 (C-8a), 58.5 (C-9), 47.3 (C-5), 
27.2 (C-8), 23.1 (C-6), 22.7 (C-7). MS (ESI +ve) m/z 188.2 
(M+H+, 100%). HRMS (ESI +ve) calculated for C9H18NO3 
(M+H+) 188.1287, found 188.1288. 
Its enantiomer 6 (10-nor-ent-steviamine) was prepared from 18b 
(0.102 mmol scale) as described above. Compound 6 was 
obtained as a brown oil (19.2 mg, 100%). [α] D
25




diyldiacetate (14) and its enantiomer 19. To a solution of 5 (3.0 
mg, 0.0160 mmol) in dry pyridine (0.06 mL, 0.68 mmol) was 
added Ac2O (0.06 mL, 0.64 mmol). The mixture was stirred at rt 
for 18 h followed by the evaporation of all volatiles. The oily 
residue was purified by flash column chromatography (increasing 
polarity from 100:0 to 0:100 petrol/EtOAc and 20:80 
MeOH/CH2Cl2 as eluent) to afford the title compound (4.3 mg, 
86%) as a yellow oil. Rf 0.38 (1:1 petrol: EtOAc). [α]D
25
 +9.4 (c 
0.2, CHCl3). MS (ESI +ve) m/z 314.3 (M+H
+, 100%). HRMS 
(ESI +ve) calculated for C15H23NO6 (M+H
+) 314.1604, found 
314.1595. IR (cm-1): 2935, 2855, 1738, 1440, 1369, 1220, 1148, 
1131, 1091, 1038. 1H NMR (500 MHz, CDCl3) δ 5.44 (t, J = 6.5 
Hz, 1H, H-2), 4.98 (dd, J = 6.5, 4.0 Hz, 1H, H-1), 4.26 (dd, J = 
11.5, 6.5 Hz, 1H, H-9), 4.09 (dd, J = 11.5, 5.5 Hz, 1H, H-9'), 3.59 
(dd, J = 13.0, 6.0 Hz, 1H, H-3), 3.04 (d, J = 12.5 Hz, 1H, H-5α),  
2.93 (dt, J = 11.5, 4.0 Hz, 1H, H-8a), 2.75−2.69 (m, 1H, H-5β), 
2.07 (s, 3H, Ac), 2.05 (s, 6H, 2Ac), 1.82−1.75 (ma, 2H, H-6, H8), 
1.49-1.42 (ma, 2H, H-7), 1.36−1.26 (m, 1H, H-6'), 1.23−1.15 (m, 
 
 
1H, H-8') [a indicates the overlapping of signals]. 13C NMR (125 
MHz, CDCl3) δ 170.8 (C=O), 170.4 (C=O), 169.9 (C=O), 75.3 
(C-1), 70.2 (C-2), 62.8 (C-8a), 61.7 (C-9), 59.6 (C-3), 47.7 (C-5), 
28.3 (C-8), 23.9 (C-6), 23.1 (C-7), 21.1 (CH3), 20.9 (CH3), 20.7 
(CH3). 
Its enantiomer 19 was prepared from 6 (0.027 mmol scale) as 
described above. Compound 19 was obtained as a yellow oil (5.3 
mg, 63%)). [α]D
25
 -9.2 (c 0.2, CHCl3). 
  
 (2R,3S,4S,E)-1,3-Bis(benzyloxy)-5-((R)-pent-4-en-2-ylamino)-
7-phenylhept-6-ene-2,4-diol (16a). To a solution of 15 (200 mg, 
0.605 mmol) in absolute ethanol (5 mL) was added (R)-pent-4-
en-2-amine.hydrochloride (9a) (73.6 mg, 0.605 mmol) followed 
by Et3N (0.084 mL, 0.605 mmol) and trans-2-phenylvinyl 
boronic acid (10) (89.6 mg, 0.605 mmol). The mixture was stirred 
at rt for 4 d, followed by the evaporation of all volatiles in vacuo. 
The residue was dissolved in CH2Cl2 (5 mL) and washed with sat. 
aq. NaHCO3 (2×5 mL). The organic layer was dried (MgSO4), 
filtered and concentrated in vacuo to afford a brown foam. 
Purification by flash column chromatography (increasing polarity 
from 0:100 to 20:80 MeOH/CH2Cl2 as eluent) afforded the title 
compound (248 mg, 82%) as a brown oil. Rf 0.45 (10:90 
MeOH/CH2Cl2). [α]D
25
 -35.7 (c 0.8, CHCl3). IR (cm
-1): 3366, 
3062, 3029, 2925, 2863, 1641, 1599, 1495, 1452, 1373, 1092, 
1072. 1H NMR (500 MHz, CDCl3) δ 7.39−7.16 (m, 15H), 6.48 
(d, J = 16.0 Hz, 1H), 6.24 (dd, J = 16.0, 9.0 Hz, 1H), 5.78−5.69 
(m, 1H), 5.08 (d, J = 11.5 Hz, 1H), 5.07 (d, J = 14.5 Hz, 1H), 
4.63, 4.55 (ABq, JAB = 12.5 Hz, 2H), 4.52, 4.45 (ABq, JAB = 11.0 
Hz, 2H), 4.05−4.02 (m, 1H), 3.95 (t, J = 4.0 Hz, 1H), 3.82 (dd, J 
= 8.5, 4.0 Hz, 1H), 3.76−3.69 (ma, 2H), 3.64 (dd, J = 7.5, 4.5 Hz, 
1H), 2.82−2.78 (m, 1H), 2.25−2.20 (m, 1H), 2.12−2.07 (m, 1H), 
1.06 (d, J = 6.5 Hz, 3H) [a indicates the overlapping of signals].  
13C NMR (125 MHz, CDCl3) δ 138.4, 138.0, 136.5, 134.6, 133.8, 
128.7, 128.5, 128.4, 128.0, 127.9, 127.5, 126.7, 126.5, 127.6, 
118.0, 79.5, 73.8, 73.7, 72.8, 71.6, 68.6, 60.2, 49.4, 39.5, 21.2. 
MS (ESI +ve) m/z 502.3 (M+H+, 100%). HRMS (ESI +ve) 
calculated for C32H40NO4 (M+H
+) 502.2957, found 502.2941. 
 
(2S,3S,4R,5S)-4-(Benzyloxy)-5-(benzyloxymethyl)-1-((R)-pent-
4-en-2-yl)-2-styrylpyrrolidin-3-ol (17a). To a solution of 16a 
(241 mg, 0.481 mmol) in anhydrous CH2Cl2 (1.6 mL) at 0 °C was 
added Et3N (0.23 mL, 1.68 mmol) under an atmosphere of N2. 
The mixture was then cooled to -10 °C followed by the addition 
of a 0.13 M solution of methanesulfonyl chloride in anhydrous 
CH2Cl2 (4.10 mL, 0.529 mmol MeSO2Cl). After complete 
addition the reaction mixture was gradually warmed to 40 °C 
over 3 h and stirred for further 30 min under gentle reflux. The 
solution was subsequently concentrated in vacuo to afford a 
brown oil. Purification by flash column chromatography 
(increasing polarity from 10:90 to 20:80 EtOAc/petrol and 20:80 
MeOH/CH2Cl2 as eluent) afforded the title compound (161 mg, 
69%) as a brown oil. Rf 0.62 (3:7 EtOAc/petrol). [α]D
25
 +20.0 (c 
0.5 CHCl3). IR (cm
-1): 3384, 3062, 3028, 2931, 2869, 1725, 
1640, 1495, 1452, 1174, 1140, 1087, 1054, 1026. 1H NMR (500 
MHz, CDCl3) δ 7.37−7.20 (m, 15H), 6.51 (d, J = 16.5 Hz, 1H), 
5.98 (dd, J = 16.0, 9.0 Hz, 1H), 5.81−5.72 (m, 1H), 4.97 (d, J = 
15.5 Hz, 1H), 4.95 (d, J = 11.5 Hz, 1H), 4.77, 4.49 (ABq, JAB = 
12.0 Hz, 2H), 4.71 (d, J = 10.0 Hz, 1H), 4.61, 4.57 (ABq, JAB = 
11.5 Hz, 2H), 4.19 (dd, J = 8.0, 5.5 Hz, 1H), 3.99 (dd, J = 8.0, 6.5 
Hz, 1H), 3.91 (d, J = 9.0 Hz, 1H), 3.62−3.54 (ma, 3H), 3.06−2.99 
(m, 1H), 2.43−2.38 (m, 1H), 1.98−1.92 (m, 1H), 1.12 (d, J = 7.0 
Hz, 1H) [a indicates the overlapping of signals]. 13C NMR (125 
MHz, CDCl3) δ 138.5, 137.5, 137.3, 137.3, 132.5, 130.6, 128.7, 
128.6, 128.5, 128.0, 127.9, 127.7, 127.5, 126.4, 116.0, 77.8, 74.9, 
73.8, 71.5, 70.5, 68.1, 59.8, 52.1, 40.4, 18.5. MS (ESI +ve) m/z 
484.3 (M+H+, 100%). HRMS (ESI +ve) calculated for 
C32H38NO3 (M+H
+) 484.2852, found 484.2837. 
 
(1S,2R,3S,5R,8aS)-2-(Benzyloxy)-3-(benzyloxymethyl)-5-
methyl-1,2,3,5,6,8a-hexahydroindolizin-1-ol (18a). To a 
solution of 17a (62.5 mg, 0.129 mmol) in anhydrous CH2Cl2 (4.4 
mL) was added via syringe a solution of Ti(Oi-Pr)4  (0.008 mL, 
0.026 mmol) in anhydrous CH2Cl2 (1.5 mL). The above solution 
was stirred at rt for 0.5 h, then Grubbs II catalyst was added (19.8 
mg, 0.023 mmol). The reaction mixture was heated at reflux at 45 
°C for 2.5 h, when TLC analysis showed complete consumption 
of 17a. The reaction mixture was then diluted with CH2Cl2 (16 
mL) and washed with sat. aq. NaHCO3 (11 mL). The aqueous 
layer was further extracted with CH2Cl2 (16 mL). The organic 
layers were dried (MgSO4) and concentrated in vacuo to afford a 
dark brown oil. Purification by flash column chromatography 
(increasing polarity from 20:80 to 10:90 petrol/EtOAc as eluent) 
afforded the title compound (23.8 mg, 83%) as a brown oil. Rf 
0.28 (1:4 EtOAc/petrol). [α]D
25
 -7.7 (c 0.9, CHCl3). IR (cm
-1): 
3376, 3030, 2925, 2869, 2358, 1636, 1453, 1375, 1265, 1207, 
1087, 1060, 1027. 1H NMR (500 MHz, CDCl3) δ 7.36-7.25 (m, 
10H), 5.73-5.70 (m, 1H), 5.60 (dd, J = 10.0, 1.0 Hz, 1H), 4.68, 
4.57 (ABq, JAB = 12.0 Hz, 2H), 4.68, 4.60 (ABq, JAB = 12.0 Hz, 
2H),  4.13 (dd, J = 8.0, 4.0 Hz, 1H), 3.96 (brs, 1H), 3.71 (brs, 
1H), 3.63 (dd, J = 9.5, 5.0 Hz, 1H), 3.55 (brd, J = 8.5 Hz, 1H), 
3.25−3.21 (m ,1H), 3.04 (brs, 1H), 2.37−2.32 (m, 1H), 1.63 (m, 
1H), 1.18 (d, J = 7.0 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 
138.4, 138.2, 128.5, 128.4, 127.9, 127.8, 127.7, 125.3, 78.4, 73.8, 
73.2, 72.6, 69.3, 62.3, 60.6, 48.8, 25.6, 20.0. MS (ESI +ve) m/z 
380.2 (M+H+, 100%). HRMS (ESI +ve) calculated for 
C24H30NO3 (M+H
+) 380.2226, found 380.2227. 
 
(1S,2R,3S,5R,8aS)-3-(Hydroxymethyl)-5-
methyloctahydroindolizine-1,2-diol (7). To a solution of 18a 
(37.0 mg, 0.098 mmol) in MeOH (2 mL) was added PdCl2 (34.6 
mg, 0.195 mmol). The mixture was stirred at rt under an 
atmosphere of H2 (balloon) for 3 h. The mixture was filtered 
through a pad of Celite and the solids were washed with MeOH. 
The combined filtrates were evaporated in vacuo and the residue 
was dissolved in water (1.5 mL) and applied to a column of 
Amberlyst A-26 (OH-) resin (3 cm). Elution with water followed 
by evaporation in vacuo afforded the title compound (19.6 mg, 
100.0%) as a brown oil. [α]D
25
 -4.6 (c 1.0, MeOH), lit.4 [α]D
20
 -1.2 
(c 1.0, MeOH). IR (cm-1): 3352, 2931, 2863, 1629, 1596, 1455, 
1381, 1339, 1121, 1096, 1059, 1028. 1H NMR (500 MHz, D2O) δ 
4.37 (t, J = 6.0 Hz, 1H, H-2), 4.09 (dd, J = 10.5, 5.5 Hz, 1H, H-
1), 3.77 (dd, J = 11.0, 9.5 Hz, 1H, H-9), 3.60 (dd, J = 11.0, 5.5 
Hz, 1H, H-9'), 3.29−3.25 (m, 1H, H-3), 3.00−2.97 (m,1H, H-8a), 
2.55−2.51 (m, 1H, H-5), 1.77−1.75 (m, 1H, H-8), 1.71−1.63 (ma, 
2H, H-6, H-8'), 1.56−1.52 (m, 1H, H-7), 1.45−1.37 (m, 1H, H-7'), 
1.16−1.08 (m, 1H, H-6'), 1.02 (d, J = 6.0 Hz, 3H, CH3) [
a 
indicates the overlapping of signals]. 13C NMR (125 MHz, D2O) 
δ 70.6 (C-1), 69.8 (C-2), 66.2 (C-3), 60.4 (C-9), 58.5 (C-8a), 55.1 
(C-5), 32.0 (C-6), 22.7 (C-8), 20.4 (CH3), 18.1 (C-7). MS (ESI 
+ve) m/z 202.1 (M+H+, 100%). HRMS (ESI +ve) calculated for 
C10H20NO3 (M+H
+) 202.1443, found 202.1450. 
 
Glycosidase inhibition assay11 
All enzymes and para-nitrophenyl substrates were purchased 
from Sigma, with the exception of -mannosidase which came 
from Megazyme. Enzymes were assayed at 27 oC in 0.1M citric 
acid / 0.2M disodium hydrogen phosphate buffers at the optimum 
pH for the enzyme. The incubation mixture consisted of 10L 
 
 
enzyme solution, 10L of 1 mg/mL aqueous solution of test 
compound and 50L of the appropriate 5 mM para-nitrophenyl 
substrate made up in buffer at the optimum pH for the enzyme. 
The reactions were stopped by addition of 70L 0.4M glycine 
(pH 10.4) during the exponential phase of the reaction, which had 
been determined at the beginning using uninhibited assays in 
which water replaced inhibitor. Final absorbances were read at 
405 nm using a Versamax microplate reader (Molecular 
Devices). Assays were carried out in triplicate, and the values 
given are means of the three replicates per assay.   
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